+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Markets Direct - Market Research Reports

Global Markets Direct relying primarily on their vast quantities of in-house information procured from years of studying the markets, are able to utilise these databases to provide the framework for their reports. As well as producing medical and pharmaceutical reports, they also offer drug pipelines, financial reports and competitor insights and benchmarking across those industries, enabling you to stay ahead of the competition.

Female Sexual Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Female Sexual Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 69 Pages
  • Global
From
Female Contraception Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Female Contraception Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 99 Pages
  • Global
From
Presbyopia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Presbyopia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 68 Pages
  • Global
From
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 42 Pages
  • Global
From
Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 51 Pages
  • Global
From
Toll Like Receptor 4 (hToll or CD284 or TLR4) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Toll Like Receptor 4 (hToll or CD284 or TLR4) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 114 Pages
  • Global
From
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 52 Pages
  • Global
From
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 67 Pages
  • Global
From
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 83 Pages
  • Global
From
Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 46 Pages
  • Global
From
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 83 Pages
  • Global
From
Recurrent Malignant Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Recurrent Malignant Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 45 Pages
  • Global
From
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase - Product Thumbnail Image

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase

  • Drug Pipelines
  • October 2018
  • 98 Pages
  • Global
From
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform - Pipeline Review, H1 2020 - Product Thumbnail Image

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform - Pipeline Review, H1 2020

  • Drug Pipelines
  • January 2020
  • 112 Pages
  • Global
From
Pancreatic Cancer - Pipeline Review, H2 2020 - Product Thumbnail Image

Pancreatic Cancer - Pipeline Review, H2 2020

  • Drug Pipelines
  • September 2020
  • 4317 Pages
  • Global
From
Dyslipidemia - Pipeline Review, H2 2020 - Product Thumbnail Image

Dyslipidemia - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 345 Pages
  • Global
From
Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) - Drugs in Development, 2021 - Product Thumbnail Image

Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) - Drugs in Development, 2021

  • Drug Pipelines
  • March 2021
  • Global
From
Middle East Respiratory Syndrome (MERS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Middle East Respiratory Syndrome (MERS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 121 Pages
  • Middle East
From
Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Pipeline Review, H2 2018 - Product Thumbnail Image

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Pipeline Review, H2 2018

  • Drug Pipelines
  • November 2018
  • 47 Pages
  • Global
From
N-Formyl Peptide Receptor 2 - Pipeline Review, H2 2019 - Product Thumbnail Image

N-Formyl Peptide Receptor 2 - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 32 Pages
  • Global
From
Loading Indicator